Merck Gruppe Logo
DE0006599905
659990
MKGAF

Merck Gruppe

Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Merck raises 2026 forecast again after strong third quarter

    Merck beat expectations in the third quarter: revenue rose to €5.63 billion, adjusted EBITDA to about €1.68 billion, and adjusted earnings per share remained at €2.32. CEO Kai Beckmann raised the 2026 targets for the third time: revenue guidance to €21.5–21.9 billion and adjusted EBITDA to €6.2–6.4 billion. The drivers are a strong life-science division and a marked recovery in the electronics business due to AI demand, while pharmaceuticals such as Mavenclad in the US are suffering from generic pressure; quarterly profit fell to €450 million after write-downs related to the CDMO sale. Merck expects the completion of the nearly €10 billion takeover of Bio-Techne still this year, which should strengthen the lab division. » Altro su wiwo.de


  • Merck sells US CDMO business to Lonza and divests five sites

    Merck is selling its US contract development and manufacturing (CDMO) business to Lonza for a mid‑three‑hundred‑million sum. The transaction includes five sites in the US with around 1,100 employees and is expected to close in mid‑2027. Under CEO Kai Beckmann, Merck intends to focus more on innovation‑driven core businesses, while Lonza gains additional production capacity in an important US market. » Altro su wiwo.de


  • Deutsche Bank assigns Merck a "hold" rating and confirms €141 target price

    Deutsche Bank Research keeps its rating for Merck at "Hold" and confirms a price target of €141. Analyst Falko Friedrichs expects a quarterly report that will beat market expectations, followed by slightly higher forecasts, with consensus estimates likely to rise only moderately. Merck shares traded intraday at €145.60, still below the target price; the stock has gained about 21.1 percent so far in 2026. » Altro su finanzen.net


  • Merck affected by tariff dispute – German pharmaceutical production faces decline

    The VFA warns that the tariff dispute with the US and low water levels could shrink German pharmaceutical production by about 2.2% in 2026 and real sales by 1.8%. Pull-forward effects from 2025 due to threats of high tariffs are now causing a counter-movement; many companies, including Merck, had previously pledged investments in the US. Additional burdens come from increased manufacturer rebates by the federal government, which could reduce investment and research by around €4 billion through 2030. Merck shares fell by about 1.09% on XETRA at one point. » Altro su finanzen.net


  • Merck acquires Silence Therapeutics for $1.3 billion with 130% premium

    Merck is buying Silence Therapeutics for $20 per ADS, representing a 130% premium to the closing price and implying an equity value of about $1.3 billion (an 82% premium versus the 30‑day VWAP). The aim is to acquire the RNAi drug candidate Divesiran to treat polycythaemia vera, which is about to enter phase 3. The deal strengthens Merck’s rare disease pipeline but carries development risks until phase‑3 data are available. » Altro su deraktionaer.de

Nel 2026, Merck Gruppe ha già distribuito 2,20 € di dividendi. L'ultimo pagamento è avvenuto a aprile.

Dati finanziari

Nell'ultimo trimestre, Merck Gruppe ha registrato ricavi pari a 5,63 Mld € e un utile netto di 450 Mln €

(EUR) settembre 2026
YoY
Ricavi 5,63 Mld 5,81%
Utile lordo 3,38 Mld 5,17%
Utile netto 450 Mln 50,11%
EBITDA 1,67 Mld 13,03%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
63,45 Mld €
Numero di azioni
434,78 Mln
Massimo/minimo a 52 settimane
160,00 € - 106,34 €
Rendimento da dividendo
1,48%
Dividendi TTM
2,20 €
Beta
0,83
Rapporto P/E
33,57
Rapporto PEG
-0,96
Rapporto P/B
2,05
Rapporto P/S
3,01

Profilo aziendale

MERCK Kommanditgesellschaft auf Aktien opera nei settori sanitario, delle scienze della vita ed elettronico in tutto il mondo. Scopre, sviluppa, produce e commercializza farmaci da prescrizione farmaceutici e biologici per il trattamento di neurologia e immunologia, oncologia, fertilità e cardiologia, metabolismo ed endocrinologia. La società fornisce inoltre prodotti, strumenti e servizi per laboratori di ricerca, per la produzione farmaceutica e biotecnologica e per laboratori industriali e di prova. Offre inoltre materiali per circuiti integrati, cristalli liquidi, diodi organici a emissione di luce, fotoresist, antenne intelligenti e soluzioni di vetrazione a cristalli liquidi, nonché pigmenti ad effetto per applicazioni nei rivestimenti automobilistici, nei cosmetici, in ambito industriale e nelle applicazioni in plastica. Ha alleanze strategiche con Pfizer Inc.; un accordo con Novartis AG; e accordi di licenza con Debiopharm International SA e MoonLake Immunotherapeutics AG. La società è stata fondata nel 1668 e ha sede a Darmstadt, in Germania. MERCK Kommanditgesellschaft auf Aktien è una controllata di E. Merck Kommanditgesellschaft.

Nome
Merck Gruppe
CEO
Kai Beckmann
Sede centrale Darmstadt, he
Germania
Sito web
Settore
Sanità
Industria
Prodotti farmaceutici
Quotazione in borsa
26/06/1998
Dipendenti 62.461

Simboli di borsa

Borsa Simbolo
Pnk
MKGAF
XETRA
MRK.DE
Frankfurt
MRK.F
Düsseldorf
MRK.DU
Hamburg
MRK.HM
Milan
1MRK.MI
London
0O14.L
SIX
MEK.SW
München
MRK.MU
Wien
MRCK.VI
🍪

Parqet  usa i cookie. Scopri di più